​

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

RCKT Stock Forecast

Rocket Pharmaceuticals (RCKT) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $5.32, with a high of $9.00 and a low of $2.95. This represents a 130.30% increase from the last price of $2.31.

$2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $5.32 Low: $2.95 Last Closed Price: $2.31

RCKT Stock Rating

Rocket Pharmaceuticals stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (73.68%), 4 Hold (21.05%), 1 Sell (5.26%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 1 4 14 Strong Sell Sell Hold Buy Strong Buy

RCKT Price Target Upside V Benchmarks

TypeNameUpside
StockRocket Pharmaceuticals130.30%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts234
Avg Price Target$3.48$5.32$5.24
Last Closing Price$2.31$2.31$2.31
Upside/Downside50.65%130.30%126.84%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 261651114
Sep, 26-661114
Aug, 26-561113
Jul, 26-561113
Jun, 26-561113
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 08, 2026Goldman Sachs$4.00$2.5457.48%73.16%
Oct 07, 2026Andrew TsaiJefferies$2.95$2.4818.95%27.71%
Sep 16, 2026Gil BlumNeedham$9.00$3.41163.93%289.61%
Jan 08, 2026Morgan Stanley$5.00$3.8928.53%116.45%
Oct 03, 2025Leerink Partners$7.00$3.26114.72%203.03%
May 28, 2025Richard LawGoldman Sachs$2.00$2.48-19.35%-13.42%
May 28, 2025Andrew TsaiJefferies$2.50$2.480.81%8.23%
Dec 30, 2024Yun ZhongWedbush$32.00$12.03166.00%1285.28%
Nov 11, 2024Whitney IjemCanaccord Genuity$39.00$17.09128.20%1588.31%
Sep 18, 2024Whitney IjemCanaccord Genuity$38.00$21.8074.31%1545.02%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 08, 2026Goldman SachsSellNeutralupgrade
Oct 07, 2026Cantor FitzgeraldOverweightOverweighthold
Oct 07, 2026JefferiesHoldHoldhold
Sep 16, 2026NeedhamHoldBuyupgrade
Mar 02, 2026Goldman SachsSellSellhold
May 28, 2025Goldman SachsNeutralHolddowngrade
May 28, 2025Goldman SachsNeutralSelldowngrade
May 28, 2025Chardan CapitalBuyBuyhold
May 16, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 30, 2024WedbushOutperforminitialise

Financial Forecast

EPS Forecast

$-25 $-12 $1 $14 $27 $40 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.26$-2.92$-2.73$-2.01---
Avg Forecast$-3.08$-3.07$-2.81$-2.28$-1.19$0.31$3.51
High Forecast$0.40$-2.71$-2.70$-0.70$0.59$36.49$7.88
Low Forecast$-11.58$-3.29$-2.87$-3.29$-2.21$-21.60$-0.03
Surprise %5.84%-4.89%-2.85%-11.84%---

Revenue Forecast

$0 $500M $1B $2B $2B $3B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$90.91K$990.00K$24.08K$58.34M$221.73M$512.27M$1.03B
High Forecast$284.34K$1.94M$47.07K$114.06M$433.48M$529.76M$2.02B
Low Forecast$11.90K$222.86K$5.42K$13.13M$49.91M$494.78M$232.19M
Surprise %-------

Net Income Forecast

$-2B $-900M $200M $1B $2B $4B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-221.86M$-245.59M$-258.75M$-223.12M---
Avg Forecast$-258.34M$-245.59M$-234.01M$-231.83M$-175.39M$-11.87M$295.17M
High Forecast$33.52M$-227.67M$-226.51M$-58.80M$49.84M$3.07B$661.61M
Low Forecast$-972.92M$-276.27M$-241.50M$-276.69M$-185.45M$-1.81B$-2.17M
Surprise %-14.12%-10.57%-3.75%---

RCKT Forecast FAQ

Is Rocket Pharmaceuticals stock a buy?

Rocket Pharmaceuticals stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Rocket Pharmaceuticals is a favorable investment for most analysts.

What is Rocket Pharmaceuticals's price target?

Rocket Pharmaceuticals's price target, set by 19 Wall Street analysts, averages $5.32 over the next 12 months. The price target range spans from $2.95 at the low end to $9 at the high end, suggesting a potential 130.30% change from the previous closing price of $2.31.

How does Rocket Pharmaceuticals stock forecast compare to its benchmarks?

Rocket Pharmaceuticals's stock forecast shows a 130.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rocket Pharmaceuticals over the past three months?

  • October 2026: 7.14% Strong Buy, 42.86% Buy, 35.71% Hold, 7.14% Sell, 7.14% Strong Sell.
  • September 2026: 0% Strong Buy, 42.86% Buy, 42.86% Hold, 7.14% Sell, 7.14% Strong Sell.
  • August 2026: 0% Strong Buy, 38.46% Buy, 46.15% Hold, 7.69% Sell, 7.69% Strong Sell.

What is Rocket Pharmaceuticals’s EPS forecast?

Rocket Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.19, marking a -40.80% decrease from the reported $-2.01 in 2025. Estimates for the following years are $0.31 in 2027, and $3.51 in 2028.

What is Rocket Pharmaceuticals’s revenue forecast?

Rocket Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $221.73M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $512.27M, and $1.03B for 2028.

What is Rocket Pharmaceuticals’s net income forecast?

Rocket Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-175M, representing a -21.40% decrease from the reported $-223M in 2025. Projections indicate $-11.874M in 2027, and $295.17M in 2028.